Frederic Bois1, Jean-Dominique Gallezot2, Ming-Qiang Zheng2, Shu-Fei Lin2, Irina Esterlis3, Kelly P Cosgrove3, Richard E Carson2, Yiyun Huang2. 1. PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: frederic.bois@yale.edu. 2. PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA. 3. PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Abstract
INTRODUCTION: The aims of the present study were to develop an optimized microfluidic method for the production of the selective nicotinic acetylcholine α4β2 receptor radiotracer [(18)F]-(-)-NCFHEB ([(18)F]-Flubatine) and to investigate its receptor binding profile and pharmacokinetic properties in rhesus monkeys in vivo. METHODS: [(18)F]-(-)-NCFHEB was prepared in two steps, a nucleophilic fluorination followed by N-Boc deprotection. PET measurements were performed in rhesus monkeys including baseline and preblocking experiments with nicotine (0.24 mg/kg). Radiometabolites in plasma were measured using HPLC. RESULTS: [(18)F]-(-)-NCFHEB was prepared in a total synthesis time of 140 min. The radiochemical purity in its final formulation was >98% and the mean specific radioactivity was 97.3 ± 16.1 GBq/μmol (n = 6) at end of synthesis (EOS). In the monkey brain, radioactivity concentration was high in the thalamus, moderate in the putamen, hippocampus, frontal cortex, and lower in the cerebellum. Nicotine blocked 98-100% of [(18)F]-(-)-NCFHEB specific binding, and the non-displaceable distribution volume (VND) was estimated at 5.9 ± 1.0 mL/cm(3) (n = 2), or 6.6 ± 1.1 mL/cm(3) after normalization by the plasma free fraction fP. Imaging data are amenable to kinetic modeling analysis using the multilinear analysis (MA1) method, and model-derived binding parameters display good test-retest reproducibility. In rhesus monkeys, [(18)F]-(-)-NCFHEB can yield robust regional binding potential (BPND) values (thalamus = 4.1 ± 1.5, frontal cortex = 1.2 ± 0.2, putamen = 0.96 ± 0.45, and cerebellum = 0.10 ± 0.29). CONCLUSION: An efficient microfluidic synthetic method was developed for preparation of [(18)F]-(-)-NCFHEB. PET examination in rhesus monkeys showed that [(18)F]-(-)-NCFHEB entered the brain readily and its regional radioactivity uptake pattern was in accordance with the known distribution of α4β2 receptors. Estimated non-displaceable binding potential (BPND) values in brain regions were better than those of [(18)F]2-FA and comparable to [(18)F]AZAN. These results confirm previous findings and support further examination of [(18)F]-(-)-NCFHEB in humans.
INTRODUCTION: The aims of the present study were to develop an optimized microfluidic method for the production of the selective nicotinic acetylcholine α4β2 receptor radiotracer [(18)F]-(-)-NCFHEB ([(18)F]-Flubatine) and to investigate its receptor binding profile and pharmacokinetic properties in rhesus monkeys in vivo. METHODS: [(18)F]-(-)-NCFHEB was prepared in two steps, a nucleophilic fluorination followed by N-Boc deprotection. PET measurements were performed in rhesus monkeys including baseline and preblocking experiments with nicotine (0.24 mg/kg). Radiometabolites in plasma were measured using HPLC. RESULTS: [(18)F]-(-)-NCFHEB was prepared in a total synthesis time of 140 min. The radiochemical purity in its final formulation was >98% and the mean specific radioactivity was 97.3 ± 16.1 GBq/μmol (n = 6) at end of synthesis (EOS). In the monkey brain, radioactivity concentration was high in the thalamus, moderate in the putamen, hippocampus, frontal cortex, and lower in the cerebellum. Nicotine blocked 98-100% of [(18)F]-(-)-NCFHEB specific binding, and the non-displaceable distribution volume (VND) was estimated at 5.9 ± 1.0 mL/cm(3) (n = 2), or 6.6 ± 1.1 mL/cm(3) after normalization by the plasma free fraction fP. Imaging data are amenable to kinetic modeling analysis using the multilinear analysis (MA1) method, and model-derived binding parameters display good test-retest reproducibility. In rhesus monkeys, [(18)F]-(-)-NCFHEB can yield robust regional binding potential (BPND) values (thalamus = 4.1 ± 1.5, frontal cortex = 1.2 ± 0.2, putamen = 0.96 ± 0.45, and cerebellum = 0.10 ± 0.29). CONCLUSION: An efficient microfluidic synthetic method was developed for preparation of [(18)F]-(-)-NCFHEB. PET examination in rhesus monkeys showed that [(18)F]-(-)-NCFHEB entered the brain readily and its regional radioactivity uptake pattern was in accordance with the known distribution of α4β2 receptors. Estimated non-displaceable binding potential (BPND) values in brain regions were better than those of [(18)F]2-FA and comparable to [(18)F]AZAN. These results confirm previous findings and support further examination of [(18)F]-(-)-NCFHEB in humans.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Alane S Kimes; Svetlana I Chefer; John A Matochik; Carlo S Contoreggi; D Bruce Vaupel; Elliot A Stein; Alexey G Mukhin Journal: Neuroimage Date: 2007-09-19 Impact factor: 6.556
Authors: S I Chefer; A G Horti; K S Lee; A O Koren; D W Jones; J G Gorey; J M Links; A G Mukhin; D R Weinberger; E D London Journal: Life Sci Date: 1998 Impact factor: 5.037
Authors: C R Breese; M J Lee; C E Adams; B Sullivan; J Logel; K M Gillen; M J Marks; A C Collins; S Leonard Journal: Neuropsychopharmacology Date: 2000-10 Impact factor: 7.853
Authors: Stephen R Baldassarri; Ansel T Hillmer; Jon Mikael Anderson; Peter Jatlow; Nabeel Nabulsi; David Labaree; Kelly P Cosgrove; Stephanie S O'Malley; Thomas Eissenberg; Suchitra Krishnan-Sarin; Irina Esterlis Journal: Nicotine Tob Res Date: 2018-03-06 Impact factor: 4.244
Authors: Hiroto Kuwabara; Yongjun Gao; Michael Stabin; Jennifer Coughlin; Sridhar Nimmagadda; Robert F Dannals; Martin G Pomper; Andrew G Horti Journal: Mol Imaging Biol Date: 2017-04 Impact factor: 3.488
Authors: A T Hillmer; I Esterlis; J D Gallezot; F Bois; M Q Zheng; N Nabulsi; S F Lin; R L Papke; Y Huang; O Sabri; R E Carson; K P Cosgrove Journal: Neuroimage Date: 2016-07-15 Impact factor: 6.556
Authors: Kelly Smart; Mika Naganawa; Stephen R Baldassarri; Nabeel Nabulsi; Jim Ropchan; Soheila Najafzadeh; Hong Gao; Antonio Navarro; Vanessa Barth; Irina Esterlis; Kelly P Cosgrove; Yiyun Huang; Richard E Carson; Ansel T Hillmer Journal: Cereb Cortex Date: 2021-05-10 Impact factor: 5.357